It seems we can’t find what you’re looking for. Perhaps searching can help.
1843 - 2025
London Health Sciences Centre – A Phase 2 Study of Poziotinib in Patients With Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, With EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20)